Bearberry (Uva Ursi)

What is bearberry (uva ursi)?

Bearberry (Arctostaphylos uva-ursi) is an evergreen shrub whose dried leaves are traditionally used for urinary symptoms. Arbutin can be converted to antimicrobial hydroquinone and excreted in urine. Its European monograph is based on traditional use, rather than proof from clinical trials.

Two facts define it: the mechanism is real, and the approved use is short courses only, a detail most supplement labels never mention.

Other names and forms it’s sold as

• Uva ursi: the Latin trade name you’ll see on most labels
• Bearberry leaf / folium: the dried-leaf drug form in pharmacopoeias
• Standardized dry extract: quantified to hydroquinone derivatives calculated as arbutin (EMA: 20–29.3% depending on solvent)
• Arbutin: the purified active itself, sold occasionally as an isolated ingredient

Where does it come from?

The leaf of a circumboreal shrub: Europe, North America, Asia. Pharmacopoeia quality requires ≥7% arbutin in the dried leaf; commercial extracts concentrate it to 20%+ hydroquinone derivatives.

How does bearberry work in the body?

Swallowed arbutin is absorbed in the small intestine, processed in the liver, and excreted in urine, where, in alkaline urine, it releases free hydroquinone, a direct antimicrobial. Human studies (Quintus et al., Planta Med 2005) confirmed urinary excretion of arbutin metabolites after oral dosing, so the compound does reach the bladder.

The catch is urine pH: hydroquinone release requires alkaline urine, which is why traditional protocols pair bearberry with alkalizing diets, and why combining it with cranberry (a urine acidifier) is counterproductive.

What is bearberry claimed to do?

Historically: “disinfect” the urinary tract and relieve burning/frequency in mild lower-UTI episodes. In modern supplements: a vaguer “urinary health” or “bladder support” role, sometimes stretched to daily prevention, which is exactly what its safety profile doesn’t allow.

What does the research show?

The evidence is “traditional use” — about what that means

The EMA’s HMPC assessment is unusually transparent: bearberry leaf preparations can be marketed for “relief of symptoms of mild, recurrent infections in the lower urinary tract” based on long-standing use, explicitly because “no clinical studies are available with preparations containing only bearberry leaf.” Antibacterial action is documented in lab work; clinical efficacy is inferred, not demonstrated.

The BRUMI trial — and the one RCT that did finish

Tóth et al. (BMJ Open, 2022) published the protocol for a multicentre randomized double-blind trial of bearberry extract vs fosfomycin vs ibuprofen for acute uncomplicated cystitis, the largest modern attempt to put uva ursi through a real trial. A smaller pilot already completed: Gágyor et al. (Clin Microbiol Infect, 2021) randomized women with uncomplicated UTI to uva-ursi extract or fosfomycin; the herbal arm fared worse, with higher symptom burden and more subsequent antibiotic use. Until BRUMI reports, every claim for bearberry rests on tradition plus mechanism, and the one finished trial points the wrong way.

Safety: real data, real limits

A risk assessment supports short-course bearberry use at the recommended dose; it does not establish the safety of continuous daily use.

A 2014 formal risk assessment (Int J Toxicol) calculated that at the EMA’s recommended daily dose (420 mg hydroquinone derivatives), free hydroquinone exposure in urine maxes ~11 µg/kg/day, comfortably under the ~100 µg/kg/day permitted-exposure estimate. So short courses appear safe. But that analysis supports therapeutic short-course dosing, not the open-ended daily use a maintenance supplement implies.

What doesn’t bearberry do?

It doesn’t treat established UTIs (EMA: serious conditions must be excluded first). It doesn’t strengthen bladder muscle, reduce urgency, or help leaks; no such claim exists even in the traditional literature. And it doesn’t belong in a take-it-every-day formula: the EMA monograph caps use at 1 week, maximum 5 times a year. A product containing bearberry in a 30-capsule monthly bottle is already outside its approved usage frame.

What dose was studied?

Nothing is “studied” for continuous supplementation; no such regimen exists in the evidence.

Which form is best?

Standardized dry extract quantified as arbutin; the EMA defines extracts at 20–29.3% hydroquinone derivatives. Plain leaf or unstandardized “bearberry” in a blend is impossible to dose-check.

Side effects

Short courses: usually mild, nausea, green-brown urine (benign hydroquinone tint), stomach upset. The concern is cumulative exposure: hydroquinone is liver- and kidney-toxic at high sustained doses in animal data, which is precisely why regulators restrict duration.

Drug interactions

• Acidifying agents (incl. cranberry, megadose vitamin C): oppose the alkaline-urine conversion arbutin needs
• Diuretics / urine-alkalizing drugs: pH-dependent effect shifts either way
• Lithium: herbal diuretics can reduce clearance (theoretical but standard caution)

Who should not take bearberry?

Pregnant and breastfeeding women, children (EMA: adult women only for the traditional indication), anyone with kidney or liver disease, anyone with an actual UTI needing antibiotics, and, per the monograph’s own limits, anyone planning to take it daily for more than a week.

What the authorities say

EMA/HMPC grants it traditional-use status for mild lower-UTI symptoms with hard duration caps. Germany’s Commission E historically approved it for urinary-tract inflammation under the same short-course logic. No authority has approved or studied it for daily maintenance use, bladder control, or incontinence, the use pattern most supplements quietly assume.

What to know about bearberry

Bearberry’s use restrictions matter more than a product’s refund period. European guidance limits courses to one week, no more than five per year, for adults. An undisclosed amount does not establish that prolonged daily use is safe or effective.